Online inquiry

IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14532MR)

This product GTTS-WQ14532MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13&IL4 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001354991.2; NM_000589.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596; 3565
UniProt ID P35225; P05112
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14532MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5970MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ4003MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ9211MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ12567MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ4193MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ9931MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ14635MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ15180MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TA-650
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW